Tivicay Approval History
Tivicay (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.
Development History and FDA Approval Process for Tivicay
|Aug 12, 2013||FDA Approves Tivicay (dolutegravir) to Treat HIV Infection|
|Dec 18, 2012||ViiV Healthcare Announces Regulatory Submissions for Dolutegravir in the EU, US and Canada|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.